Precision Oncology Market Report Scope & Overview:
The Precision Oncology Market was valued at USD 110.38 billion in 2024 and is expected to reach USD 225.65 billion by 2032, growing at a CAGR of 9.35% from 2025-2032.
The precision oncology market is expected to experience significant growth in the coming years due to the high demand for personalized treatments in the fight against cancer. Personalized medicine not only provides patients with more information to make informed health decisions but also leads to increased patient engagement and a sense of control over their treatment plans. This ultimately contributes to better health outcomes, increased revenue for healthcare providers, and stronger patient-therapist relationships. The Department of Health and Human Services reports that actively engaged patients are more likely to adhere to their treatment plans. The integration of precision oncology with AI, big data analytics, and digital health options is expected to enhance patient outcomes and accelerate drug development.
Get More Information on Precision Oncology Market - Request Sample Report
Nanotechnology and AI have significantly improved the performance of cancer treatment by enabling the development of more precise diagnostic and treatment platforms. For instance, AI-based imaging has enhanced disease characterization on MRIs, leading to more accurate results. Additionally, nanomedicine has demonstrated the potential for revolutionizing cancer treatment through the AI-based design of biological devices known as nanomaterials. The National Institutes of Health (NIH) is focusing on the development of AI-enhanced nanosensors and other biological and nanomaterial devices, including nanoelectronics biosensors.
Precision Oncology Market Trends
-
Rising prevalence of cancer and demand for targeted therapies are fueling precision oncology adoption.
-
Integration of genomics, biomarkers, and molecular diagnostics is enabling more personalized treatment strategies.
-
AI and big data analytics are accelerating drug discovery, clinical decision-making, and patient stratification.
-
Growing use of companion diagnostics with targeted drugs is enhancing treatment accuracy and outcomes.
-
Liquid biopsies and next-gen sequencing (NGS) are transforming non-invasive cancer detection and monitoring.
-
Pharmaceutical companies are increasing collaborations with diagnostic firms to co-develop precision therapies.
-
Shift toward value-based healthcare is driving adoption of precision oncology for improved cost-effectiveness.
-
Expanding clinical trials in immuno-oncology and gene-based therapies is widening the treatment pipeline.
Precision Oncology Market Growth Drivers:
-
Rapid Advancements in Genomic Research and Growing Demand for Personalized Medicine Propel the Precision Oncology Market
The Precision Oncology Market is primarily driven by rapid advancements in genomic research, enabling detailed understanding of cancer at the molecular and genetic levels. These developments facilitate the identification of specific biomarkers, mutations, and pathways, allowing for highly targeted therapies. Simultaneously, there is a growing demand for personalized medicine as patients and healthcare providers increasingly prefer treatments tailored to individual genetic profiles, which improve efficacy and minimize side effects. Together, these factors accelerate the adoption of precision oncology solutions across hospitals, research centers, and biotechnology firms globally, fueling significant market growth.
Precision Oncology Market Restraints:
-
High Costs of Precision Oncology Treatments Pose a Significant Restraint on Market Growth
One of the key challenges restraining the Precision Oncology Market is the high cost of targeted therapies, genomic testing, and personalized treatment plans. These expenses limit accessibility, particularly in low- and middle-income regions, and place a financial burden on patients and healthcare systems. Additionally, the need for advanced laboratory infrastructure, specialized personnel, and ongoing monitoring further increases treatment costs. As a result, adoption rates of precision oncology solutions may be slower than expected, and market expansion is constrained despite strong technological advancements and growing awareness of personalized cancer therapies worldwide.
Precision Oncology Market Opportunities:
-
Integration of Artificial Intelligence and Big Data Analytics in Precision Oncology Presents Significant Growth Opportunities
The Precision Oncology Market stands to benefit greatly from the integration of artificial intelligence (AI) and big data analytics. These technologies enable the analysis of vast genomic, clinical, and patient data to identify patterns, predict treatment responses, and design personalized therapies with higher precision. AI-driven tools can accelerate drug discovery, optimize clinical trial design, and enhance decision-making for oncologists. The growing adoption of digital health platforms and advanced analytics in oncology provides opportunities for improved patient outcomes, cost efficiency, and faster market expansion, positioning AI and big data as key growth enablers.
Precision Oncology Market Segment Analysis
By Product, Therapeutics segment dominated in 2023 with a 72% revenue share
The therapeutics segment dominated the market with a 72% revenue share in 2024. This was mainly due to the increasing approval of tumor-agnostic therapies and the unique features of therapeutics targeting specific proteins or mutations driving cancer growth.
Additionally, the diagnostic tools segment is projected to experience rapid growth, with a 10.6% compound annual growth rate (CAGR) from 2025 to 2032. The diagnostic products available in the precision oncology market will be involved in verification and validation activities, relying on the outcomes from current tests. Moreover, the emergence of technological products for diagnostics has improved decision-making, leading to better clinical outcomes, reduced unnecessary therapies, minimized side effects, and prevention of drug resistance.
By Cancer Type, Breast cancer segment held the largest market share of 42% in 2024
By 2024, the breast cancer held the largest market share of 42%. This is subject to the increased focus on breast cancer screening, diagnosis, and surgical and radiation techniques. Furthermore, with expanded research activities, and technology revelations for DNA sequencing, relating to the early detection of breast cancer by patients the overall prognosis presents a growth factor for novel methods of development, especially precision oncology. Moreover, the cervical cancer segment is expected to offer the fastest CAGR of 10.7% over the forecast period. This is because of the growing research projects development in the sector including product launches like the CDC announcing a funding award of USD215 million.
Precision Oncology Market Regional Analysis
North America Precision Oncology Market Insights
In 2024, North America led the industry accounted for 43% of the market share. The industry in this region is competitive with the presence of most of the major market players including Thermo Fisher Scientific Inc., Invitae Corporation, Illumina, Inc., and Laboratory Corporation of America Holding. Further, a high cancer population, several types of research, the development of a diagnostic software platform, and increased healthcare spending offer new service growth opportunities.
Need any customization research on Precision Oncology Market - Enquiry Now
Asia Pacific Precision Oncology Market Insights
The Asia Pacific Precision Oncology Market is experiencing rapid growth, driven by rising cancer prevalence, increasing healthcare expenditure, and expanding genomic research initiatives. Countries like China, Japan, and India are witnessing higher adoption of targeted therapies and advanced diagnostic tools. Government support, growing awareness of personalized medicine, and investments in healthcare infrastructure are further accelerating market expansion across the region.
Europe Precision Oncology Market Insights
Europe’s Precision Oncology Market is witnessing steady growth due to advanced healthcare infrastructure, strong research initiatives, and high adoption of personalized cancer therapies. Countries such as Germany, France, and the UK are investing in genomic testing, targeted treatments, and clinical trials. Increasing awareness among patients, supportive government policies, and collaborations between biotech firms and healthcare providers are driving the region’s expanding precision oncology landscape.
Middle East & Africa and Latin America Precision Oncology Market Insights
The Precision Oncology Market in the Middle East & Africa and Latin America is growing steadily, driven by rising cancer incidence, increasing healthcare investments, and expanding access to advanced diagnostics and targeted therapies. Emerging economies are adopting personalized medicine initiatives, while government support and international collaborations enhance research and treatment capabilities, creating significant opportunities for market expansion across these regions.
Precision Oncology Market Competitive Landscape:
Illumina
Illumina is a leading contributor to the Precision Oncology Market, offering advanced genomic sequencing solutions that enable detailed cancer profiling and personalized treatment strategies. Its platforms facilitate high-throughput DNA and RNA analysis, supporting early diagnosis, therapy selection, and clinical research. By integrating innovative sequencing technologies, Illumina empowers clinicians and researchers to deliver precise, targeted oncology care, improving patient outcomes and advancing the adoption of personalized medicine worldwide.
-
Illumina (2025) Expanded its clinical oncology portfolio with FDA-approved TSO Comprehensive and new Pillar oncoReveal CDx panels—enabling in-house tumor profiling and accelerating targeted therapy decisions in community and academic clinical labs.
Foundation Medicine
Foundation Medicine is a prominent player in the Precision Oncology Market, specializing in comprehensive genomic profiling to guide personalized cancer therapies. Its solutions enable clinicians to identify actionable mutations, select targeted treatments, and improve patient outcomes. By integrating advanced diagnostics with real-world clinical data, Foundation Medicine supports precision oncology adoption across hospitals, research centers, and clinical trials, driving innovation in cancer care and expanding access to tailored therapeutic strategies.
-
Foundation Medicine (2025) Announced more than 15 abstracts to be presented at the ASCO 2025 meeting, showcasing clinical advances and real-world applications of its high-quality biomarker tests for informing cancer care.
-
Foundation Medicine (2024) Introduced FoundationOne®Liquid CDx as the first liquid biopsy FDA-approved companion diagnostic for tepotinib in MET exon 14 skipping non–small cell lung cancer, broadening precision treatment access.
-
Foundation Medicine & Roche (2023) Reported improved outcomes in a global trial (CUPISCO) using comprehensive genomic profiling (CGP) to guide treatment for patients with cancer of unknown primary, validating CGP’s therapeutic value.
Key Players
Some of the Precision Oncology Market Companies
-
Thermo Fisher Scientific Inc.
-
Invitae Corporation
-
Qiagen N.V.
-
Illumina, Inc.
-
Laboratory Corporation of America Holding
-
Exact Sciences Corporation
-
Rain Oncology Inc.
-
Strata Oncology, Inc.
-
Xilis, Inc.
-
Variantyx, Inc.
-
Bioserve
-
Relay Therapeutics
-
Acrivon Therapeutics
-
Foundation Medicine, Inc.
-
Guardant Health, Inc.
-
Nanostring Technologies, Inc.
-
Caris Life Sciences
-
Bio-Rad Laboratories, Inc.
-
Freenome Holdings, Inc.
-
Tempus Labs, Inc.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | US$ 110.38 Billion |
| Market Size by 2032 | US$ 225.65 Billion |
| CAGR | CAGR of 9.35% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | •By Product Type (Diagnostics, Therapeutics) •By Cancer Type (Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Others) •By End Use (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Healthcare Data Companies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Thermo Fisher Scientific Inc., Invitae Corporation, Qiagen N.V., Illumina, Inc., Laboratory Corporation of America Holding, Exact Sciences Corporation, Rain Oncology Inc., Strata Oncology, Inc., Xilis, Inc., Variantyx, Inc., Bioserve, Relay Therapeutics, Acrivon Therapeutics, Foundation Medicine, Inc., Guardant Health, Inc., Nanostring Technologies, Inc., Caris Life Sciences, Bio-Rad Laboratories, Inc., Freenome Holdings, Inc., Tempus Labs, Inc. |
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Product
2.3.2 Market Size By Cancer Type
2.3.3 Market Size By End-Use
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Treatment Cost & Pricing Trends
4.1.1 Overview
4.1.2 Average Cost of Precision Oncology Therapies by Cancer Type
4.1.3 Cost Comparison: Targeted Therapy vs. Immunotherapy vs. Chemotherapy
4.1.4 Reimbursement & Insurance Coverage Ratios by Region
4.1.5 Patient Out-of-Pocket Expenditure Trends
4.2 Patient & Demographic Insights
4.2.1 Overview
4.2.2 Number of Cancer Patients Eligible for Precision Oncology (Global & Regional)
4.2.3 Adoption Rates by Age Group & Gender
4.2.4 Patient Willingness-to-Pay for Personalized Treatment
4.2.5 Ratio of Early vs. Late-Stage Patients Receiving Precision Oncology
4.3 Genomic & Biomarker Data Statistics
4.3.1 Overview
4.3.2 Number of Patients Undergoing Genomic Sequencing Annually
4.3.3 Frequency of Biomarker Testing in Oncology Cases
4.3.4 Database Growth of Genomic Profiles (Public & Private)
4.3.5 Biomarker-Linked Therapy Success Rates
4.4 Clinical Trials & Research Insights
4.4.1 Overview
4.4.2 Number of Ongoing Clinical Trials in Precision Oncology
4.4.3 Distribution of Trials by Therapy Type (Targeted, Immunotherapy, Cell-Based)
4.4.4 Average Trial Enrollment Size & Success Rates
4.4.5 Investment Trends in Translational Research & Clinical Pipelines
4.5 Technology Adoption Metrics
4.5.1 Overview
4.5.2 Penetration of Next-Generation Sequencing (NGS) in Oncology Diagnostics
4.5.3 Use of AI & Big Data in Precision Oncology Treatment Planning
4.5.4 Digital Pathology & Imaging Integration Rates
4.5.5 Adoption of Companion Diagnostics Across Regions
5. Precision Oncology Market Segmental Analysis & Forecast, By Product, 2021 – 2032, Value (Usd Billion)
5.1 Introduction
5.2 Diagnostics
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Therapeutics
6. Precision Oncology Market Segmental Analysis & Forecast, By Cancer Type, 2021 – 2032, Value (Usd Billion)
6.1 Introduction
6.2 Breast Cancer
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Colorectal Cancer
6.4 Cervical Cancer
6.5 Prostate Cancer
6.6 Lung Cancer
6.7 Others
7. Precision Oncology Market Segmental Analysis & Forecast, By End-Use, 2021 – 2032, Value (Usd Billion)
7.1 Introduction
7.2 Hospitals & Diagnostic Laboratories
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Pharmaceutical & Biotechnology Companies
7.4 Healthcare Data Companies
8. Precision Oncology Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (Usd Billion)
8.1 Introduction
8.2 North America
8.2.1 Key Trends
8.2.2 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.2.3 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.2.4 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.2.5 Precision Oncology Market Size & Forecast, By Country, 2021 – 2032
8.2.5.1 USA
8.2.5.1.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.2.5.1.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.2.5.1.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.2.5.2 Canada
8.2.5.2.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.2.5.2.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.2.5.2.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.3 Europe
8.3.1 Key Trends
8.3.2 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.3.3 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.3.4 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.3.5 Precision Oncology Market Size & Forecast, By Country, 2021 – 2032
8.3.5.1 Germany
8.3.5.1.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.3.5.1.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.3.5.1.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.3.5.2 UK
8.3.5.2.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.3.5.2.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.3.5.2.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.3.5.3 France
8.3.5.3.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.3.5.3.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.3.5.3.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.3.5.4 Italy
8.3.5.4.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.3.5.4.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.3.5.4.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.3.5.5 Spain
8.3.5.5.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.3.5.5.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.3.5.5.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.3.5.6 Russia
8.3.5.6.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.3.5.6.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.3.5.6.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.3.5.7 Poland
8.3.5.7.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.3.5.7.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.3.5.7.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.3.5.8 Rest of Europe
8.3.5.8.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.3.5.8.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.3.5.8.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.4 Asia-Pacific
8.4.1 Key Trends
8.4.2 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.4.3 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.4.4 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.4.5 Precision Oncology Market Size & Forecast, By Country, 2021 – 2032
8.4.5.1 China
8.4.5.1.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.4.5.1.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.4.5.1.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.4.5.2 India
8.4.5.2.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.4.5.2.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.4.5.2.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.4.5.3 Japan
8.4.5.3.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.4.5.3.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.4.5.3.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.4.5.4 South Korea
8.4.5.4.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.4.5.4.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.4.5.4.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.4.5.5 Australia
8.4.5.5.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.4.5.5.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.4.5.5.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.4.5.6 ASEAN Countries
8.4.5.6.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.4.5.6.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.4.5.6.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.4.5.7 Rest of Asia-Pacific
8.4.5.7.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.4.5.7.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.4.5.7.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.5 Latin America
8.5.1 Key Trends
8.5.2 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.5.3 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.5.4 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.5.5 Precision Oncology Market Size & Forecast, By Country, 2021 – 2032
8.5.5.1 Brazil
8.5.5.1.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.5.5.1.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.5.5.1.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.5.5.2 Argentina
8.5.5.2.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.5.5.2.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.5.5.2.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.5.5.3 Mexico
8.5.5.3.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.5.5.3.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.5.5.3.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.5.5.4 Colombia
8.5.5.4.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.5.5.4.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.5.5.4.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.5.5.5 Rest of Latin America
8.5.5.5.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.5.5.5.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.5.5.5.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.6 Middle East & Africa
8.6.1 Key Trends
8.6.2 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.6.3 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.6.4 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.6.5 Precision Oncology Market Size & Forecast, By Country, 2021 – 2032
8.6.5.1 UAE
8.6.5.1.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.6.5.1.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.6.5.1.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.6.5.2 Saudi Arabia
8.6.5.2.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.6.5.2.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.6.5.2.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.6.5.3 Qatar
8.6.5.3.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.6.5.3.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.6.5.3.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.6.5.4 Egypt
8.6.5.4.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.6.5.4.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.6.5.4.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.6.5.5 South Africa
8.6.5.5.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.6.5.5.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.6.5.5.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
8.6.5.6 Rest of Middle East & Africa
8.6.5.6.1 Precision Oncology Market Size & Forecast, By Product, 2021 – 2032
8.6.5.6.2 Precision Oncology Market Size & Forecast, By Cancer Type, 2021 – 2032
8.6.5.6.3 Precision Oncology Market Size & Forecast, By End-Use, 2021 – 2032
9. Competitive Landscape
9.1 Key Players' Positioning
9.2 Competitive Developments
9.2.1 Key Strategies Adopted (%), By Key Players, 2024
9.2.2 Year-Wise Strategies & Development, 2021 – 2025
9.2.3 Number Of Strategies Adopted By Key Players, 2024
9.3 Market Share Analysis, 2024
9.4 Product/Service & Application Benchmarking
9.4.1 Product/Service Specifications & Features By Key Players
9.4.2 Product/Service Heatmap By Key Players
9.4.3 Application Heatmap By Key Players
9.5 Industry Start-Up & Innovation Landscape
9.6 Key Company Profiles
9.6.1 Thermo Fisher Scientific Inc.
9.6.1.1 Company Overview & Snapshot
9.6.1.2 Product/Service Portfolio
9.6.1.3 Key Company Financials
9.6.1.4 SWOT Analysis
9.6.2 Invitae Corporation
9.6.3 Qiagen N.V.
9.6.4 Illumina, Inc.
9.6.5 Laboratory Corporation of America Holding
9.6.6 Exact Sciences Corporation
9.6.7 Rain Oncology Inc.
9.6.8 Strata Oncology, Inc.
9.6.9 Xilis, Inc.
9.6.10 Variantyx, Inc.
9.6.11 Bioserve
9.6.12 Relay Therapeutics
9.6.13 Acrivon Therapeutics
9.6.14 Foundation Medicine, Inc.
9.6.15 Guardant Health, Inc.
9.6.16 Nanostring Technologies, Inc.
9.6.17 Caris Life Sciences
9.6.18 Bio-Rad Laboratories, Inc.
9.6.19 Freenome Holdings, Inc.
9.6.20 Tempus Labs, Inc.
10. Analyst Recommendations
10.1 SNS Insider Opportunity Map
10.2 Industry Low-Hanging Fruit Assessment
10.3 Market Entry & Growth Strategy
10.4 Analyst Viewpoint & Suggestions On Market Growth
11. Assumptions
12. Disclaimer
13. Appendix
13.1 List Of Tables
13.2 List Of Figures
Key Segments
By Product
-
Diagnostics
-
Therapeutics
By Cancer Type
-
Breast Cancer
-
Colorectal Cancer
-
Cervical Cancer
-
Prostate Cancer
-
Lung Cancer
-
Others
By End-Use
-
Hospitals & Diagnostic Laboratories
-
Pharmaceutical & Biotechnology Companies
-
Healthcare Data Companies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Eastern Europe
-
Poland
-
Romania
-
Hungary
-
Turkey
-
Rest of Eastern Europe
-
-
Western Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Netherlands
-
Switzerland
-
Austria
-
Rest of Western Europe
-
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Vietnam
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
Middle East
-
UAE
-
Egypt
-
Saudi Arabia
-
Qatar
-
Rest of the Middle East
-
-
Africa
-
Nigeria
-
South Africa
-
Rest of Africa
-
Latin America
-
Brazil
-
Argentina
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
-
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Product Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Product Matrix which gives a detailed comparison of the product portfolio of each company
-
Geographic Analysis
-
Additional countries in any of the regions
-
Company Information
-
Detailed analysis and profiling of additional market players (Up to five)
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
